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Abstract 1 
Cholangiocarcinoma (CCA) is increasing in incidence worldwide and is resistant to 2 
chemotherapeutic agents, making treatment of CCA a major challenge. Previous studies 3 
reported that natural sulfated polysaccharides (SPs) disrupted growth factor receptor 4 
activation in cancer cells. The present study, therefore, aimed at investigating the anti-5 
proliferation effect of sulfated galactans (SG) isolated from the red seaweed Gracilaria 6 
fisheri (G. fisheri) on CCA cell lines. Direct binding activity of SG to CCA cells, epidermal 7 
growth factor (EGF) and epidermal growth factor receptor (EGFR) were determined.  The 8 
effect of SG on proliferation of CCA cells was investigated. Cell cycle analyses and 9 
expression of signaling molecules associated with proliferation were also determined.  The 10 
results demonstrated that SG bound directly to EGFR.  SG inhibited proliferation of various 11 
CCA cell lines by inhibiting EGFR and extracellular signal-regulated kinases (ERK) 12 
phosphorylation, and inhibited EGF-induced increased cell proliferation. Cell cycle analyses 13 
showed that SG induced cell cycle arrest at the G0/G1 phase, down-regulated cell cycle genes 14 
and proteins (cyclin-D, cyclin-E, Cdk-4, Cdk-2), and up-regulated the tumor suppressor 15 
protein P53 and the cyclin-dependent kinase inhibitor P21. Taken together, these data 16 
demonstrate that SG from G. fisheri inhibited proliferation of CCA cells, and its mechanism 17 
of inhibition is mediated, to some extent, by inhibitory effects on EGFR activation and 18 
EGFR/ERK signaling pathway. SG presents a potential EGFR targeted molecule, which may 19 
be further clinically developed in a combination therapy for CCA treatment. 20 
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Introduction 27 
Cholangiocarcinoma (CCA) is a malignant transformation of cholangiocytes, the epithelial 28 
cells lining the biliary tree (Khan et al, 2005). In the Northeastern part of Thailand, CCA is 29 
associated with infection of the liver fluke, Opisthorchis viverrini (Sriamporn et al., 2004; 30 
Sripa et al., 2011). The disease has a high fatality rate due to a combination of late diagnosis 31 
and lack of treatment options (Tushar, 2002). Combinations of radiation and chemotherapy 32 
are used in an attempt to improve survival of patients, but, these therapies have many side-33 
effects and in patients with metastatic or inoperable disease, survival is not significantly 34 
improved (Benavides et al., 2015). Current standard of care is gemcitabine and cisplatin, but 35 
this only increased survival by 2-3 months in trials in the US and Europe, and data on trials in 36 
Thailand is still missing.  37 
Heparin-binding EGF-like growth factor (HB-EGF) is a member of epidermal growth 38 
factor (EGF) family. Generally, it binds epidermal growth factor receptor (EGFR) using co-39 
receptor heparan sulfate proteoglycans (HSPGs) (Iwamoto et al., 2010). CCA from various 40 
sources have been shown to express the EGFR and other heparin sulfate binding growth 41 
factors (Yoshikawa et al., 2007; Hoffmann et al., 2013; Clapéron et al., 2014) and inhibition 42 
of EGFR activation has been shown to prevent growth of CCA cells in vitro. However, a 43 
clinical trial of the EGFR antibody panitumumab, carried out on patients in Europe did not 44 
find any effect of EGFR inhibition on patient survival. A number of new trials are ongoing in 45 
Europe and the US, including a combination of gemcitabine and cisplatin, with vandetanib 46 
(Kessler et al., 2016), an antagonist to EGFR and vascular endothelial growth factor receptor 47 
(VEGFR). Vandetanib has also been shown to decrease the growth of human CCA cell lines 48 
(Yoshikawa et al., 2009). These results indicate that heparin-binding growth factors such as 49 
EGF and vascular endothelial growth factor (VEGF) could play a role in cholangiocarcinoma 50 
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progression and could be potential targets for therapy. However, all these trials, and most of 51 
the cell biology is undertaken on CCA from European and US patients, which have been 52 
shown to be drastically different in their biology from CCA from Thai patients. The 53 
molecular etiology of Opisthorchis related CCA has recently been shown to be different from 54 
elsewhere in the world (Chan-on et al., 2013), with much higher levels of p53 mutation in 55 
Thai CCA patients than European ones. It is therefore important to determine the effect of 56 
heparin binding factor inhibition in CCA from patients with O. viverrini associated cancers.  57 
Sulfated polysaccharides (SPs) are compounds found in extracts from various natural 58 
sources such as terrestrial (Silva et al., 2012), and marine plants (Vishchuk et al., 2011), 59 
mushrooms (Zhang et al., 2012), and animals (Chen et al., 2012). SPs have been shown to 60 
regulate proliferation, migration, angiogenesis and differentiation in a variety of cells (Costa 61 
et al., 2010). SPs trigger signaling pathways involving in anti-proliferation and migration 62 
(Wu et al., 2006; Wu et al., 2011). They have been shown to inhibit cancer cell proliferation 63 
by induction of cell cycle arrest (Wong et al., 2007) and by decreased growth factor secretion 64 
in cancer cells (Cao & Lin, 2006).  65 
Previous studies reported that SPs could either be stimulatory or inhibitory. For 66 
instance, SPs extracted from an edible herbal plant, enhanced the binding of fibroblast growth 67 
factor and its receptor, leading to the proliferation of neural stem/progenitor cells  (Zhang et 68 
al., 2010). In contrast, inhibitory effects of SPs on the binding of basic-fibroblast growth 69 
factor and its co-receptor, leading to decreased proliferation of cancer cells (Xiong-Zhi et al, 70 
2011). SPs extracted from brown seaweed namely, fucoidan interrupted EGF-induced cell 71 
transformation by blockage the EGF and EGFR interaction (Lee et al, 2008). This suggests 72 
that SPs could act either as activators or competitors in the recognition of growth factors by 73 
their co-receptors, depending on cell type and SPs type. 74 
Recently, sulfated galactans (SG) obtained from Gracilaria fisheri (G. fisheri), a red 75 
seaweed cultivated in South East Asia, have been isolated (Wongprasert et al, 2014). Several 76 
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biological activities have been reported including anti-viral (Rudtanatip et al., 2014), anti-77 
coagulant (Pereira et al., 2005), and immune stimulating activities (Rudtanatip et al., 2015). 78 
Various species of Gracilaria have been claimed to exhibit anti-malignant activity against 79 
breast cancer and colon cancer (Zandi et al., 2010). We previously demonstrated that the 80 
structure of SG extracted from G. fisheri is a polysaccharide of galactose backbone and 81 
contains a high percentage of sulfates (Wongprasert et al., 2014), similar in structure to 82 
HSPGs. Due to the structural similarity of SG and HSPGs, we hypothesized that SG could 83 
imitate a co-receptor on the cell membrane and interact with growth factors or their receptors, 84 
effecting an inhibitory effect on cancer cell activity. Therefore, this study aimed to evaluate 85 
any anti-proliferation activity of SG in CCA cells lines, and determine any underlying anti-86 
proliferation mechanism of SG, especially through EGF-EGFR interaction 87 
. 88 
Materials and Methods 89 
Sulfated galactans (SG) from Gracilaria fisheri (G. fisheri) 90 
G. fisheri was collected from Suratthani Province, Thailand, washed, epiphytes removed, and 91 
dried. Dried sample was extracted to obtain SG following the previously described protocol, 92 
and the SG yielded was 3% of the seaweed dry weight (Wongprasert et al., 2014). The 93 
structure of SG analyzed by NMR and FT-IR consists of 3-linked-β-D-galactopyranose (G) 94 
and 4-linked 3,6-anhydro-α-L-galactopyranose (LA) or α-L-galactose-6-sulfate (L6S) with 95 
partial methylation (CH3) at C-2 of LA and C-6 of G, and presence of sulfation on C-4 and C-96 
6 of D-galactopyranose units (G4S and G6S) (Fig. 1).  97 
 98 
Cell culture  99 
CCA cells (HuCCA-1, RMCCA-1 and KKU-M213) established from CCA tissue fragments 100 
of Thai patients were tested for an anti-proliferation effect of SG.  HuCCA-1 (Sirisinha et al., 101 
1991) and KKU-M213 are derived from a patient with intrahepatic bile duct CCA. RMCCA-102 
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1 is derived from a patient with peripheral CCA (Rattanasinganchan et al., 2006). They were 103 
cultured at 37°C, 5% CO2 in Ham F-12 nutrient mixture (Ham F-12) (Gibco Invitrogen, 104 
USA) containing 1.17 g/L sodium bicarbonate (NaHCO3), 5% FBS (Sigma Aldrich, USA) 105 
and penicillin (100 units/mL) plus streptomycin (100 µg/mL) (Wiscent Inc. P.O., Canada).   106 
 107 
Direct binding of FITC-SG to HuCCA-1 cells by confocal laser scanning microscopy (CLSM) 108 
SG conjugated FITC was prepared as previously described (Rudtanatip et al., 2015). Briefly, 109 
one hundred milligrams of SG was dissolved in 1 mL of DMSO containing 15 µL of 110 
pyridine. The SG mixture was mixed with powdered FITC (40 mg) and 2 mg/mL of dibutylin 111 
dilaurate, and then heated at 95 °C for 2 h. After precipitation with absolute ethanol overnight 112 
at 4 °C, the mixture was centrifuged at 900×g for 15 min, and supernatant discarded. The 113 
pellet was dissolved in 2-4 mL of PBS pH 7.4, the unbound FITC was removed with an 114 
Amicon ®Ultra Centrifugal Filter (Ultracel-30K) (Merck, Germany), centrifuged at 900×g, 115 
for 5-10 min, and then the solution freeze-dried by Freeze Dry Supermodulyo-230 (Thermo 116 
Scientific, USA). 117 
HuCCA-1 cells were grown on poly-L-lysine-coated-coverslip in a 24-well plate 118 
overnight at 37 °C.  Cells were incubated with FITC without SG as a control or with FITC-119 
SG at 37 °C for 2 h in the dark, then washed thrice with PBS pH 7.4. The coverslips were 120 
fixed with 4% paraformaldehyde in PBS for 10 min at RT. After washing in PBS, they were 121 
mounted with mounting medium containing TO-PRO-3 (Sigma Aldrich, USA), and 122 
examined under a Confocal Laser Scanning Microscope (FV10i-DOC) (Olympus, Japan). 123 
 124 
The SG-EGF binding using FAR-Western blot analysis 125 
The binding activity of SG with EGF protein was determined by Far-Western blot analysis as 126 
previously described (Rudtanatip et al., 2015).  The recombinant EGF protein, lectin proteins 127 
(positive controls) and 2% BSA (a negative control) were separated on 15% gel-SDS-PAGE, 128 
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stained with Coomassie blue, and blotted onto nitrocellulose membrane. The membrane was 129 
incubated with 100 µg/mL of SG overnight at 4°C. After washing with 0.05% Tween-20 in 130 
PBS (PBS-T), membrane was blocked with 10% non-fat dry milk in PBS-T for 2-4 h at room 131 
temperature. The membrane was incubated with primary anti LM5 monoclonal antibody 132 
(Plant Probes, UK), which is specific to (1è4)-β-D-galactans of SG, overnight at 4°C, 133 
followed by incubation with goat anti-rat HRP conjugated secondary antibody for 2 h at room 134 
temperature. Complex of SG-proteins was visualized using the ECL kit and visualized on 135 
Hyperfilm ECL. 136 
 137 
Co-immunoprecipitation for SG-EGFR binding 138 
Cell membrane protein was extracted in cold TE buffer (20 mM Tris-HCl, pH 7.5, 100 mM 139 
NaCl, 1 mM EDTA, pH 8.0), homogenized with a hypodermic needle gauge size 26, 140 
ultracentrifuged at 40,000×g, 4 °C for 10 min, the supernatant removed and pellet re-141 
suspended in cold TE buffer containing 2% Triton X-100 and protease inhibitor. After 142 
ultracentrifugation at 100,000×g, 4 °C for 30 min, the supernatant was collected, and protein 143 
concentration determined.  144 
Pull down assay: The membrane protein lysate was incubated with SG (ratio 1:1), 145 
shaking overnight at 4 °C. The Co-IP was performed using SureBeads™Protein G magnetic 146 
Beads (Bio-Rad, USA) following the manufacturer’s protocol. Briefly, 100 µL of SureBeads 147 
was washed with 0.1% Tween-20 in PBS pH 7.4 (PBS-T), magnetized and supernatant 148 
discarded three times. The beads were then incubated with 100 µl of anti LM5 monoclonal 149 
antibody or IgG (Santa Cruz Biotechnology, USA) on a rotator for 10 min at room 150 
temperature, magnetized, and supernatant discarded. The membrane protein lysate was 151 
incubated with SG (ratio 1:1), shaken overnight at 4 °C, and then mixed with the beads, 152 
rotated for 60 min at room temperature.  After washing with PBS-T three times, 20 µL of 153 
glycine (20 mM) pH 2.0 was added to the tube, incubated 5 min at room temperature, 154 
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magnetized, and then eluent containing immunocomplex protein collected. The eluent was 155 
neutralized in 2 µL of 1 M phosphate buffer (0.05 M dibasic sodium phosphate, 0.05 M 156 
monobasic sodium phosphate), pH 7.4. The immunocomplex protein was separated on a 10% 157 
polyacrylamide gel by SDS-PAGE, blotted onto nitrocellulose membrane (Merck Germany), 158 
incubated with the primary anti EGFR antibody or IgG (Santa Cruz Biotechnology, USA) 159 
then followed with HRP-conjugated secondary antibody. Immunoprecipitated proteins were 160 
detected using the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, UK) and 161 
visualized on Hyperfilm ECL (Piscataway, USA). The protein lysate without co-IP was also 162 
immunoblotted with anti-EGFR antibody as a control.  To confirm binding, EGFR in the cell 163 
lysate was pulled down using Surebeads conjugated with anti-EGFR antibody or IgG, and the 164 
eluent containing EGFR was separated on 10% SDS-PAGE gel and blotted onto 165 
nitrocellulose membrane. The membrane was incubated with 100 µg/mL of SG for overnight 166 
at 4°C, immunoblotted with the anti LM5 monoclonal antibody or IgG, incubated with the 167 
HRP-conjugated secondary antibody, detected using ECL kit, and visualized on Hyperfilm 168 
ECL.  169 
 170 
MTT assay  171 
CCA cells (HuCCA-1, RMCCA-1 and KKU-M213) were grown overnight in a 96-well plate 172 
at density 1×104 cells/well. Cells were incubated with different concentrations of SG (0, 10, 173 
20, 50 and 100 µg/mL) for 48 h.  After incubation cell proliferation was determined using 174 
methyl thiazolium bromide (MTT) assay. Briefly, 100 µL of MTT solution (0.5 mg/mL) 175 
(Sigma Aldrich, USA) was added to each well and incubated for 4 h at 37oC in the dark. 176 
After incubation, 100 µL of dimethyl sulfoxide (DMSO) (Merck, Germany) was added to 177 
each well, and the absorbance of the sample was measured at OD 490 nm by a Versamax 178 
microplate reader using SoftMax® Pro 4.8 analysis software (Molecular Devices, USA). 179 
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 To determine an ability of SG to inhibit epidermal growth factor (EGF) induced CCA 180 
cell growth, HuCCA-1 cells were treated with SG (10 and 50 µg/mL) or EGF (5 ng/mL) 181 
(Cell signaling Technology, USA) or both SG and EGF. After incubation for 48 h, cell 182 
proliferation was determined by MTT assay.  183 
 184 
Cell cycle analysis using flow cytometry 185 
HuCCA-1 cells were starved with free fetal bovine serum (FBS) overnight to synchronize 186 
cells to quiescent stage. Cells were incubated with or without SG (10, 50 µg/mL) for 24 h, 187 
then collected, washed twice with phosphate buffer saline (PBS), pH 7.4 and centrifuged. 188 
Cells were suspended in 70% cold ethanol in PBS pH 7.4 at -20° C for 30 min, washed twice 189 
in 1 mL of PBS, and then 5 µL of 10 mg/mL of RNase (Roche Diagnostics, USA) was added. 190 
After incubation at 37° C for 30 min, cells were stained in 100 µL of 0.5 mg/mL propidium 191 
iodide (PI) (Sigma Aldrich, USA) at 4°C in the dark for 10 min. DNA content of cells was 192 
determined using BD FACSCanto™ flow cytometer (BD Biosciences, USA). 193 
 194 
Reverse transcription PCR of cyclin-D, cyclin-E, cdk-4 and cdk-2 195 
The key regulators driving cells from G0/G1 phase to S phase include cyclin-D, cyclin-E, cdk-196 
4, and cdk-2. Therefore, we determined the mRNA expression of these genes. After 24 h 197 
incubation, cells were collected and washed twice with PBS. Total RNA was extracted using 198 
Trizol reagent as manufacturer’s instruction (Molecular research Center, Inc, USA). The 199 
concentration and purity of RNA were determined using a Nano drop-2000C 200 
spectrophotometer (Thermo Scientific, USA). Total RNA (1 µg) was reverse-transcribed to 201 
cDNA in a total volume of 20µl system by using the Revert Aid First Strand cDNA Synthesis 202 
Kit (Thermo Scientific, USA) following the manufacturer’s protocol.  The PCR product was 203 
obtained by using Thermo Scientific Phusion High-Fidelity DNA polymerase (Thermo 204 
Scientific, USA) following the manufacturer’s protocol. The PCR conditions were as follows: 205 
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1 cycle of initial denaturation at 98 °C for 30 sec, 27-35 cycles of denaturation at 98 °C for 206 
10 sec, annealing temperature and number of cycles for each particular genes, extension at 72 207 
°C for 30 sec, and final extension 1 cycle at 72 °C for 5 min.  The specific PCR primer 208 
sequences and amplification conditions of cyclin-D, cyclin-E, cdk-4 and cdk-2 are shown in 209 
Table 1. The PCR products were separated on 1.5% W/V agarose gel, tris-borate-210 
ethylenediaminetetraacetic acid (TBE)-buffered, containing 0.5 µg/mL of ethidium bromide. 211 
The PCR bands were visualized using UVP EpiChemi III Darkroom (UVP Bioimaging 212 
Systems, USA). Expression of cyclin-D, cyclin-E, cdk-4 and cdk-2 were quantified by 213 
ImageJ analysis program (from NIH website by Scion Corporation, Frederick, MD). 214 
 215 
Western blot analysis  216 
The cyclin/cdk complexes are negatively regulated by cdk inhibitor, P21; and transcription of 217 
P21 is induced by a tumor suppressor protein P53. EGFR activation by its ligands EGF leads 218 
to EGFR phosphorylation, thereby stimulating downstream signaling cascades using the 219 
MAPK/ERK pathway involved in cell proliferation. We, therefore, determined the protein 220 
expression levels of the key regulators, P21, P53, p-EGFR and p-ERK by Western blotting. 221 
HuCCA-1 cells were incubated with or without SG (10, 50 µg/mL) for 24 h. Cells were 222 
collected and whole cell lysates were prepared in lysis buffer (3 mM MgCl2, 1 mM EGTA, 10 223 
mM sodium pyrophosphate (NaPpi), 10 mM sodium orthovanadate (Na3VO4), 50 mM 224 
sodium fluoride (NaF) and 100 X protease inhibitor solution) and centrifuged at 8,500×g for 225 
15 min at 4°C. The supernatant was collected to determine protein concentration by BCA 226 
assay using the Pierce™ BCA Protein Assay Kit (Thermo Scientific, USA). Proteins were 227 
separated on 10-12.5% gel SDS-PAGE, blotted onto a nitrocellulose membrane (Merck, 228 
Germany), and incubated with primary antibodies:- cyclin-D, cyclin-E, P53, P21, EGFR, p-229 
EGFR, and p-ERK antibodies (Santa Cruz Biotechnology, USA), followed by incubation 230 
with horseradish-peroxidase-conjugated (HRP) secondary antibody. Anti-alpha (α)-tubulin 231 
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antibody (Santa Cruz Biotechnology, USA) was also probed in all blots as an internal control. 232 
Proteins were detected using the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, 233 
UK) and visualized on Hyperfilm ECL (Piscataway, USA). Expression of protein was 234 
quantified by ImageJ analysis program (from NIH website by Scion Corporation, Frederick, 235 
MD). 236 
 To determine whether SG could decrease EGF induced EGFR activation, cells were 237 
treated with SG (10, 50 µg/mL) with or without EGF (5 ng/mL) or with only EGF for 24 h at 238 
37 °C.  In addition, to determine whether SG mediated inhibiting effects through EGFR, cells 239 
were pretreated with the anti EGFR antibody (Sigma Aldrich, USA) to neutralize EGFR for 2 240 
h prior exposure to SG or EGF for 24 h. After incubation, cells were collected for protein 241 
extraction and expression of p-EGFR determined.  242 
  243 
Statistical analysis 244 
All methods were performed in three independent experiments. Data are presented as means 245 
± SEM and statistically analyzed by one-way ANOVA followed by Turkey’s multiple 246 
comparison tests using GraphPad Prism program version 6 (GraphPad software, USA). 247 
Difference with p-values less than 0.05 were considered statistically significant. 248 
 249 
Results 250 
The interaction of SG with HuCCA-1 cells  251 
The binding activity of SG to HuCCA-1 cells was determined by immunofluorescence and 252 
Co-IP experiments. The CLSM micrographs revealed that FITC conjugated SG could bind to 253 
HuCCA-1 cells whereas FITC by itself showed no binding activity (Fig. 2A). SG interaction 254 
with EGFR was examined by Co-IP experiments.  SG was allowed to bind with HuCCA-1 255 
cell membrane protein lysate and the SG-protein complex was pulled down using anti LM5 256 
antibody (a specific antibody against SG). The result demonstrated that SG-protein complex 257 
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showed a positive immunoblot with anti-EGFR antibody. In the converse experiment, cell 258 
lysate immunoprecipitated with anti EGFR antibody, incubated with SG, and followed with 259 
immunoblotting with the anti-LM5 antibody also showed an immunoreactive band at the same 260 
size (Fig. 2B). The cell membrane lysate without co-IP (a positive control) probed with anti-261 
EGFR antibody showed a positive EGFR band, while the cell membrane lysate from co-IP 262 
probed with IgG of the same species of the antibodies revealed a negative immunoblot. These 263 
results suggested that SG could interact with EGFR.  Moreover, an ability of SG to bind with 264 
EGF was evaluated by Far-Western blot analysis. The result revealed that SG could interact 265 
to controls including commercial lectin, RCA and WGA, but could not interact with the 266 
recombinant EGF tested (Fig. 2C).  267 
 268 
SG inhibited CCA cell proliferation and EGFR activation 269 
Various CCA cell lines included HuCCA-1, RMCCA-1 and KKU-M213 cells were used to 270 
test the anti-proliferation effect of SG. The results revealed that SG at different 271 
concentrations (0, 10, 20, 50 and 100 µg/mL) significantly decreased proliferation in all 272 
tested CCA cell lines (Fig. 3 A-C). Proliferation, migration/invasion and angiogenesis 273 
activities in various cancer cells are mediated through activation of EGFR signaling pathway. 274 
We therefore investigated the EGFR-MAPKs/ERK signaling pathway, a major downstream 275 
signaling cascade of EGFR activation.  The results demonstrated that cells treated with SG 276 
showed levels of EGFR expression not different from control but decreased level of p-EGFR 277 
(Fig. 4A) and  p-ERK (Fig. 4B). 278 
 279 
SG suppressed EGF induced EGFR activation 280 
We further determined whether SG could inhibit EGF induced HuCCA-1 cell proliferation. 281 
To test this, cells were pretreated with or without SG (10 and 50 µg/mL) before stimulating 282 
with EGF (5 ng/mL). The results showed that treatment of cells with SG alone at 283 
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concentrations of 10 and 50 µg/mL decreased cell number to 78 ± 2.4 and 75 ± 6.4% of 284 
control, respectively. Treatment of cells with EGF alone increased cell number to 128 ± 6.4% 285 
of control. Treatment of cells with SG before stimulation with EGF decreased cell number to 286 
94 ± 2.7 and 88 ± 1.2% of control, respectively, significantly less than cells treated with EGF 287 
alone (Fig. 5A). Cells treated with SG alone or with SG prior exposure to EGF decreased 288 
levels of p-EGFR expression from control. Both showed that phosphorylation of EGFR was 289 
less than in cells treated with EGF alone (Fig. 5B).  Moreover, when EGFR was neutralized 290 
with anti EGFR antibody prior SG treatment, cells restored the level of p-EGFR to that of 291 
control (Fig. 6). Collectively, the results suggested that SG might interact with EGFR and 292 
mediate inhibition of cell proliferation, in part, by preventing endogenous activation of the 293 
EGFR-MAPK/ERK pathway. 294 
 295 
SG inhibited CCA cells proliferation by arresting cells at G0/G1 phase  296 
To investigate the effect of SG on cell cycle, HuCCA-1 cells were treated with SG (10 and 50 297 
µg/mL) and cell populations determined. Flow cytometry showed that cells treated with SG 298 
significantly increased the percentage of cells in G0/G1 phase and decreased those in S phase 299 
compared with controls (Fig. 7). The results suggested that SG retarded the cells at G0/G1 300 
phase. 301 
We further determined expressions of the key regulators in the G0/G1 phase transition 302 
and tumor suppressor proteins that control cell cycle in HuCCA-1 cells. RT-PCR analysis 303 
showed that cells treated with SG induced a dose dependent decrease in mRNA transcripts of 304 
cyclin-D, cyclin-E, cdk-4 and cdk-2 (Fig. 8). Western blot analysis showed that cells treated 305 
with SG decreased protein levels of cyclin-D, cyclin-E (Fig. 9A, B), and concurrently 306 
increased expression levels of the tumor suppressor protein P53 and cyclin-dependent kinase 307 
inhibitor P21 compared with control (Fig. 9C, D). These results indicated that SG induced 308 
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HuCCA-1 cells arrested at G0/G1 phase by downregulating cyclin-D, cyclin-E, cdk-4 and 309 
cdk-2 and upregulating P53 and P21.  310 
  311 
Discussion and Conclusion 312 
Cholangiocarcinoma (CCA) is a malignant biliary epithelial cell transformation, which has 313 
very poor prognosis due to its resistance to radiotherapy and chemotherapy (Zografos et al., 314 
2011). CCA is more common in North East Thailand than anywhere else in the world due to 315 
endemic O. viverrini infection. Critically, while most trials of anti-cancer drugs have been 316 
tried in western cholangiocarcinoma, CCA from Thailand are genetically distinct, and have 317 
different activated signal transduction pathways. Therefore it is critical to understand the 318 
biology of CCA derived from patients with O. viverrini associated carcinoma. It is well 319 
established that growth factors and their receptor activation are important signals in 320 
regulating cancer cell bioactivities. Many growth factor receptors require HSPGs as a co-321 
receptor to bind and activate them (Afratis et al., 2012). EGFR is a member of the ErbB 322 
family of receptor tyrosine kinases, and plays a critical role in development and cancer cell 323 
progression. Dimerization and phosphorylation of EGFR by EGF activates a series of 324 
intracellular signaling cascades to affect transcription of genes regulating cancer cell 325 
proliferation, reduced apoptosis, invasion and metastasis and also stimulates tumor-induced 326 
angiogenesis (Hynes & MacDonald, 2009). Previous studies have shown that EGFR is 327 
overexpressed in CCA human samples (Harder et al., 2009). EGFR activation triggers the 328 
MAPK-ERK signaling pathway in cholangiocytes (Yoon et al., 2004). 329 
 It has been reported that natural SPs have structures similar to HSPGs and imitate the 330 
function of HSPGs.  They can act to block the binding of growth factor/receptor and co-331 
receptor, resulting in suppression the activation of receptor downstream signaling pathway in 332 
cancer cells (Lee et al., 2008; Cheng et al., 2012). Recently, we have isolated SPs – 333 
specifically SG - from red seaweed Gracilaria fisheri (G. fisheri) with structure similar to 334 
 15 
heparan sulfate (Wongprasert et al., 2014). SG might compete for binding with the growth 335 
factor/receptor or co-receptor due to its structural similarity to HSPGs. Therefore, we have a 336 
hypothesis that SG might interact with EGFR or EGF, thereby preventing EGFR activation, 337 
and thus decreasing CCA cells proliferation. In the present study, we show that SG could 338 
bind to HuCCA-1 cells. Additionally, far western blotting and Co-IP assay revealed that SG 339 
did not interact directly with EGF but interacted with EGFR. SG demonstrated the anti-340 
proliferation effects against three different CCA cell lines derived from Thai patients, 341 
(HuCCA-1, RMCCA-1 and KKU-M213). We investigated the effects of SG on EGFR 342 
signaling cascades regulating proliferation in HuccA-1 cells. Our results reveal that SG has 343 
no effect on EGFR expression but down-regulated phosphorylation of EGFR and ERK in 344 
HuCCA-1 cells. Moreover, it inhibited EGF-induced proliferation. Additionally, when EGFR 345 
was neutralized, (reducing pEGFR on the cell membrane) and followed by SG treatment, 346 
cells restored the levels of p-EGFR to normal. These results suggest that SG could not 347 
downregulate EGFR but required interaction with EGFR to reduce EGFR activation. This 348 
competitive binding of SG might interfere with receptor dimerization thus decreasing the 349 
level of p-EGFR and p-ERK, the signaling molecules in EGFR/MAPK/ERK pathway 350 
controlling cell cycle.  The specific binding site of SG on EGFR and the underlined scenario 351 
by which SG mediated suppress EGFR activation need further investigation. 352 
SG exhibited anti-cancer activity against Thai cholangiocarcinoma by modulating cell 353 
cycle regulators and inhibiting ERK expression. This is consistent with findings from other 354 
groups on other SPs (Zhang et al., 2012; Park et al., 2015). SG inhibited HuCCA-1 cells 355 
proliferation by arresting cells at G0/G1 phase, with no apoptosis (no sub-G1 peak in cell 356 
cycle). This is in contrast with a previous study, which reported that fucoidans, SPs from 357 
brown seaweed, induced apoptosis and inhibited cell viability of bladder cancer cells, T24 358 
(Park et al., 2014).  At G0/G1 phase, the main cell-cycle regulators are cyclin/cdk complexes 359 
(cyclin-D/cdk-4, cdk-6, cyclin-E/cdk-2) for transition to S-phase. These regulators are 360 
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negatively regulated by cdk inhibitors (CDKI), P21 (Dobashi et al., 2003) which are 361 
important for abnormal or cancer cells being able to evade the G1 restriction point, and 362 
continue to proliferate in S, G2 and M phases (Fuster & Esko, 2005). P21 binds to and 363 
inhibits the kinase activity of CDKs leading to growth arrest at specific stages in the cell 364 
(Sherr & Roberts, 1999). Indeed, transcription of p21 can be induced by a tumor suppressor 365 
protein P53, and thus it acts as an indirect effector of tumor suppressor pathways for 366 
promoting cell cycle arrest (Benson et al., 2014). Previous studies in Thai CCA cell lines 367 
have shown that CCA cell treatment with chemotherapeutic agents such as doxorubicin and 368 
gemcitabine up-regulated P53 and P21 expression (Zeekpudsa et al., 2014), and dicoumarol 369 
at non-cytotoxic concentrations enhanced the level of P53 protein (Buranrat et al., 2010), 370 
expression of which was associated with the strong anti-proliferative effect.  p53 is the most 371 
commonly mutated tumor suppressor gene associated with the development of human cancer 372 
and has been implicated in cholangiocarcinoma development by various studies.  It is noted 373 
that the Thai CCA cell lines and CCA tissues expressed both wild type and mutant p53 374 
(Nutthasirikul et al., 2013). Mutant p53 was non-functional, while wild type p53 mediated 375 
p53 transcriptional activation. Our results showed that increased expression of P21 was 376 
associated with P53 proteins suggesting that SG might induce P21 up-regulation via 377 
activation of wild type p53 transcription, and the inhibiting effect of SG on CCA cell 378 
proliferation can occur in cells expressing mutant p53.  However, this study could not 379 
identify specific P53 isoforms due to the limitation of the P53 antibody in Western blot 380 
analysis. Collectively, the results suggest that SG reduced proliferation of HuCCA-1 cells by 381 
arresting the cells at G1 phase through the down-regulation of cyclin-D, cyclin-E, cdk-4 and 382 
cdk-2, and also by induction of P53 and P21.  383 
The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein 384 
(MAP) kinase signaling pathway is among the key mechanisms that transmit signals upon 385 
receptor activation from the cell surface to the nucleus, eliciting proliferative and survival 386 
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signals in cancer cells. In particular, its role in cell cycle progression in G1 phase and cell 387 
proliferation is well established. Growth factors induce phosphorylation and activation of 388 
ERK, which subsequently is translocated from the cytoplasm to the nucleus, where p-ERK 389 
activates several nuclear ERK targets (Sun et al., 2015). Here we show that SG decreased 390 
HuCCA-1 cell proliferation by inhibiting cell cycle progression was correlated with 391 
decreased expression of p-EGFR and p-ERK. Our results are consistent with a previous study 392 
in mouse epidermal JB6Cl41 cells that marine SPs from Laminaria guryanovae decreased 393 
expression of p-EGFR (Lee et al., 2008).  The previous reports demonstrated that ERK 394 
activation is required for induction of cyclin-D up-regulation and reduction of P53 and P21 395 
for driving cells from G0/G1 to S phase (Massagué, 2004). Our study suggests that SG might 396 
inhibit ERK activation leading to the reduction of cyclin-D, along with the induction of the 397 
cdk inhibitor P21 to stabilize cyclin-D/cdk4 complexes, thus cells fail to enter S-phase.  398 
Taken together, this study demonstrates the anti-proliferation effect of SG from G. 399 
fisheri against HuCCA-1 cells is by arresting the cell at G1 phase, and its inhibition 400 
mechanism is mediated, to a lesser extent, through EGFR and EGFR/MAPK/ERK signaling. 401 
SG presents a potential EGFR targeted molecule, which may be further clinically developed 402 
as an adjuvant for enhancing the efficacy of chemotherapeutic agents for CCA treatment. 403 
Moreover, the SG demonstrates a potential to overcome drug resistance in CCA with mutated 404 
p53 treatment. 405 
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Legends 555 
Fig. 1 The structural feature of sulfated galactans (SG) from G. fisheri. SG is a partially 556 
pyruvated and methylated agarose structure, which consists of 3-linked-β-d-galactopyranose 557 
(G) and 4-linked 3,6-anhydro-α-L-galactopyranose (LA) or α-l-galactose-6-sulfate (L6S) 558 
with partial methylaion (CH3) at C-2 of LA and C-6 of G, and presence of sulfation on C-4 559 
and C-6 of d-galactopyranose units (G4S and G6S) (Wongprasert et al., 2014).  560 
  561 
Fig. 2 Representative data of SG interaction with CCA cells. (A) Confocal laser scanning 562 
micrographs showed the adherence of FITC-SG to HuCCA-1 cells in X-Y and X-Z axis 563 
whereas control cells incubated with FITC only showed no green fluorescence. FITC-SG is 564 
represented in green color and nuclei stained with TO-PRO-3 represent in red color. Scale 565 
bars = 150 µm. (B) Left: cell membrane lysate was allowed to bind with SG, and proteins 566 
bound with SG were pulled down using anti-LM5 antibody. The eluent was then 567 
immunoblotted with anti-EGFR antibody. Middle: Cell membrane lysate without co-IP was 568 
blotted with anti-EGFR antibody as an EGFR blotted control. Right: in the converse 569 
experiment, cell membrane lysate was pulled down with anti-EGFR antibody, and then the 570 
eluent was incubated with SG before immunoblotted with anti-LM5 antibody. The results 571 
revealed the interaction of SG with EGFR. The lysate was also probed with IgG of the same 572 
species of the antibodies raised, and the results were negative.  (C) Right: SDS-PAGE gels 573 
showing coomassie-brilliant blue staining of lectins (RCA, WGA) as positive controls, 574 
recombinant EGF and BSA (negative control). Left:  Far-Western blotting showing SG 575 
bound to lectins (RCA and WGA), but not BSA and the recombinant EGF. 576 
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 577 
Fig. 3 The effect of SG on CCA cell proliferation. (A) HuCCA-1, (B) RMCCA-1 and (C) 578 
KKU-M213 were treated with different concentrations of SG (0, 10, 20, 50 and 100 µg/mL) 579 
for 48 h. Cell viability was measured using MTT assay. Results are presented as a mean ± 580 
SEM of triplets independent experiments; *p < 0.05 compared to control. 581 
 582 
Fig. 4 Western blot analysis showing the relative expressions of (A) EGFR and p-EGFR and 583 
(B) p-ERK to α -tubulin protein in HuCCA-1 cells after treatment with SG for 24 h. Results 584 
are presented as a mean ± SEM of triplets independent experiments; *p < 0.05 compared to 585 
the respective control. 586 
 587 
Fig. 5 SG inhibited EGF induced HuCCA-1 cells proliferation and EGFR activation. (A) Cell 588 
viability of HuCCA-1 cells measured by MTT assay. HuCCA-1 cells were pretreated with 589 
SG (10 and 50 µg/mL) followed with or without EGF (5 ng/mL) for 24 h. (B) Western blot 590 
analysis of p-EGFR in HuCCA-1 cells and relative expression of p-EGFR to α -tubulin in 591 
different treatment groups. Cells were pre-treated with or without SG and then post-treated 592 
with or without EGF for 24 h. Results are presented as a mean ± SEM of three independent 593 
experiments; *p < 0.05 compared to control, #p < 0.05 compared to EGF-treated group. 594 
 595 
Fig. 6 Western blot analysis showed the amount of p-EGFR relative to α -tubulin in different 596 
treatment groups. HuCCA-1 cells were treated with or without anti-EGFR antibody for 2 h 597 
prior to exposure to SG for 24 h, and p-EGFR was determined. Results are presented as a 598 
mean ± SEM of triplets independent experiments; *p < 0.05 compared to control. 599 
 600 
 24 
Fig. 7 Representative experiments of flow cytometry showing the cell cycle distribution in 601 
HuCCA-1 cells.  Cells treated with SG or without SG for 24 h and mean percentages of cells 602 
in the G0/G1, S, and G2/M phases of cell cycle. 603 
 604 
Fig. 8 (A) RT-PCR bands showing expression at the transcriptional level of cyclin-D, cyclin-605 
E, cdk-4 and cdk-2 in HuCCA-1 cells after treatment with SG for 24 h. (B) Densitometry 606 
values of cyclin-D, cyclin-E, cdk-4 and cdk-2 mRNA relative to GAPDH. Results are 607 
presented as a mean ± SEM of triplets independent experiments; *p < 0.05 compared to the 608 
respective control. 609 
 610 
Fig. 9 (A) Western blot analysis showed the expression of cyclin-D and cyclin-E proteins. (B)  611 
The relative expression of cyclin-D and cyclin-E proteins to α -tubulin protein. (C) Western 612 
blot analysis showed the expression of P53 and P21 proteins. (D) The relative expression of 613 
P53 and P21 proteins to α -tubulin protein. Results are presented as a mean ± SEM of three 614 
independent experiments; *p < 0.05 compared to the respective control. 615 
 616 
Table 1. Specific primers and conditions for determination of the expression at the 617 
transcriptional level of cyclin-D, cyclin-E, cdk-4 and cdk-2 in HuCCA-1 treated with SG.  618 
